(Q30358429)

20 June 2017

2 references

23 October 2022

Antiviral agents active against influenza A viruses. (English)

1 reference

20 June 2017

Erik De Clercq

1

0 references

publication date

1 December 2006

2 references

Nature Reviews Drug Discovery

20 June 2017

23 October 2022

2 references

20 June 2017

23 October 2022

5

1 reference

20 June 2017

issue

12

1 reference

20 June 2017

page(s)

1015-1025

1 reference

Strategies for containing an emerging influenza pandemic in Southeast Asia

20 June 2017

cites work

1 reference

Strategies for mitigating an influenza pandemic

31 March 2020

1 reference

Avian influenza viruses and their implication for human health.

31 March 2020

1 reference

Avian influenza A (H5N1) infection in humans

31 March 2020

1 reference

1918 Influenza: the mother of all pandemics

31 March 2020

1 reference

Influenza pandemics of the 20th century

31 March 2020

1 reference

The origins of pandemic influenza--lessons from the 1918 virus.

31 March 2020

1 reference

Influenza: old and new threats

31 March 2020

1 reference

ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE).

31 March 2020

1 reference

Influenza: lessons from past pandemics, warnings from current incidents.

31 March 2020

1 reference

Analysis of the pore structure of the influenza A virus M(2) ion channel by the substituted-cysteine accessibility method

31 March 2020

1 reference

Influenza virus M2 protein: a molecular modelling study of the ion channel.

31 March 2020

1 reference

Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States

31 March 2020

1 reference

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

31 March 2020

1 reference

Synthesis and antiviral activity evaluation of some aminoadamantane derivatives

31 March 2020

1 reference

Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.

31 March 2020

1 reference

Synthesis of 2-(2-adamantyl)piperidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling

31 March 2020

1 reference

Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus-identification of aminoadamantane derivatives bearing two pharmacophoric amine groups

31 March 2020

1 reference

Are the 2-isomers of the drug rimantadine active anti-influenza A agents?

31 March 2020

1 reference

Heterocyclic rimantadine analogues with antiviral activity

31 March 2020

1 reference

Heterocyclic rimantadine analogues with antiviral activity

31 March 2020

1 reference

The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus.

31 March 2020

1 reference

Antivirals and antiviral strategies

31 March 2020

1 reference

Neuraminidase inhibitors for influenza

31 March 2020

1 reference

Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium

31 March 2020

1 reference

Avian flu: influenza virus receptors in the human airway

31 March 2020

1 reference

H5N1 Virus Attachment to Lower Respiratory Tract

31 March 2020

1 reference

Rational design of potent sialidase-based inhibitors of influenza virus replication

31 March 2020

1 reference

Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity

31 March 2020

1 reference

Early administration of oral oseltamivir increases the benefits of influenza treatment

31 March 2020

1 reference

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

31 March 2020

1 reference

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial

31 March 2020

1 reference

Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis

31 March 2020

1 reference

A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons.

31 March 2020

1 reference

Strategies in the design of antiviral drugs

31 March 2020

1 reference

The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.

31 March 2020

1 reference

Resistance of influenza viruses to neuraminidase inhibitors--a review.

31 March 2020

1 reference

Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.

31 March 2020

1 reference

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

31 March 2020

1 reference

Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.

31 March 2020

1 reference

Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets

31 March 2020

1 reference

Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets

31 March 2020

1 reference

Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility

31 March 2020

1 reference

A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community

31 March 2020

1 reference

Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus.

31 March 2020

1 reference

Avian flu: isolation of drug-resistant H5N1 virus.

31 March 2020

1 reference

Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir

31 March 2020

1 reference

The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.

31 March 2020

1 reference

Oseltamivir resistance during treatment of influenza A (H5N1) infection

31 March 2020

1 reference

Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.

31 March 2020

1 reference

Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities

31 March 2020

1 reference

In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201

31 March 2020

1 reference

Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo

31 March 2020

1 reference

Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity

31 March 2020

1 reference

Syntheses and neuraminidase inhibitory activity of multisubstituted cyclopentane amide derivatives

31 March 2020

1 reference

Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores

31 March 2020

1 reference

Enantioselective synthesis of antiinfluenza compound A-315675.

31 March 2020

1 reference

Total synthesis of A-315675: a potent inhibitor of influenza neuraminidase

31 March 2020

1 reference

In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication

31 March 2020

1 reference

Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors

31 March 2020

1 reference

Design, synthesis, and structural analysis of inhibitors of influenza neuraminidase containing a 2,3-disubstituted tetrahydrofuran-5-carboxylic acid core.

31 March 2020

1 reference

Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors

31 March 2020

1 reference

In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.

31 March 2020

1 reference

Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors

31 March 2020

1 reference

Anti-influenza virus activity of peramivir in mice with single intramuscular injection

31 March 2020

1 reference

Synthesis and anti-influenza virus activity of 7-O-alkylated derivatives related to zanamivir

31 March 2020

1 reference

Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir

31 March 2020

1 reference

Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza.

31 March 2020

1 reference

Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen

31 March 2020

1 reference

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

31 March 2020

1 reference

In vitro and in vivo influenza virus-inhibitory effects of viramidine

31 March 2020

1 reference

Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection

31 March 2020

1 reference

Lassa fever. Effective therapy with ribavirin

31 March 2020

1 reference

Prospective, Double-Blind, Concurrent, Placebo-Controlled Clinical Trial of Intravenous Ribavirin Therapy of Hemorrhagic Fever with Renal Syndrome

31 March 2020

1 reference

Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.

31 March 2020

1 reference

Polymeric inhibitor of influenza virus attachment protects mice from experimental influenza infection

31 March 2020

1 reference

Polymer-bound 6' sialyl-N-acetyllactosamine protects mice infected by influenza virus

31 March 2020

1 reference

Inhibition of influenza virus production in virus-infected mice by RNA interference

31 March 2020

1 reference

Protection against lethal influenza virus challenge by RNA interference in vivo.

31 March 2020

1 reference

Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque

31 March 2020

1 reference

In vitro assembly of PB2 with a PB1-PA dimer supports a new model of assembly of influenza A virus polymerase subunits into a functional trimeric complex

31 March 2020

1 reference

The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04.

31 March 2020

1 reference

Purine 2'-deoxy-2'-fluororibosides as antiinfluenza virus agents

31 March 2020

1 reference

Inhibition of influenza virus transcription by 2'-deoxy-2'-fluoroguanosine

31 March 2020

1 reference

In vitro and in vivo activities of anti-influenza virus compound T-705.

31 March 2020

1 reference

In vitro and in vivo activities of T-705 and oseltamivir against influenza virus

31 March 2020

1 reference

Mechanism of action of T-705 against influenza virus

31 March 2020

1 reference

Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds

31 March 2020

1 reference

A novel antiviral agent which inhibits the endonuclease of influenza viruses

31 March 2020

1 reference

A novel class of potent influenza virus inhibitors: polysubstituted acylthiourea and its fused heterocycle derivatives

31 March 2020

1 reference

Synthesis and biological evaluation of novel bisheterocycle-containing compounds as potential anti-influenza virus agents

31 March 2020

1 reference

Virus interference. I. The interferon

31 March 2020

1 reference

Absence of interferon in lungs fom fatal cases of influenza

31 March 2020

1 reference

Intranasal Lymphoblastoid Interferon ("Well fer on") Prophylaxis Against Rhinovirus and Influenza Virus in Volunteers

31 March 2020

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

31 March 2020

1 reference

Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes

31 March 2020

1 reference

Immunoprophylactic strategies against respiratory influenza virus infection

31 March 2020

1 reference

Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection

31 March 2020

1 reference

Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases

31 March 2020

1 reference

Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade

31 March 2020

1 reference

Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase Calpha-mediated activation of ERK signaling

31 March 2020

1 reference

The CPSF30 binding site on the NS1A protein of influenza A virus is a potential antiviral target.

31 March 2020

1 reference

Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C.

31 March 2020

1 reference

Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro

31 March 2020

1 reference

Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells

31 March 2020

1 reference

Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants

31 March 2020

1 reference

Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction

31 March 2020

1 reference

12 December 2020

Synthesis of influenza neuraminidase inhibitors

1 reference

12 December 2020

Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.

1 reference

12 December 2020

The preventive effect of human interferon-alpha on influenza infection; modification of clinical manifestations of influenza in children in a closed community

1 reference

12 December 2020

Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza

1 reference

12 December 2020

Adamantane resistance in influenza A.

1 reference

12 December 2020

Ribavirin aerosol treatment of influenza

1 reference

12 December 2020

Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD2175

1 reference

20 June 2017

0 references

1 reference